ADAGENE
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.
ADAGENE
Industry:
Biotechnology Medical Oncology Therapeutics
Founded:
2011-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.adagene.com
Total Employee:
51+
Status:
Active
Contact:
+051287773632
Email Addresses:
[email protected]
Total Funding:
155 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Google Font API Google Tag Manager WordPress Google Analytics Amazon SSL By Default
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Arcturus Therapeutics
Arcturus Therapeutics is a clinical-stage company specializing in mRNA medicines and vaccines.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Innolake Biopharm
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Trymed
Trymed is a clinical research company that seeks new treatments in oncology and other therapeutic areas.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
F-Prime Capital
F-Prime Capital investment in Series D - Adagene
Eight Roads Ventures
Eight Roads Ventures investment in Series D - Adagene
Wuxi Venture Capital Group
Wuxi Venture Capital Group investment in Series D - Adagene
General Atlantic
General Atlantic investment in Series D - Adagene
Sequoia Capital China
Sequoia Capital China investment in Series D - Adagene
Gopher Asset Management
Gopher Asset Management investment in Series C - Adagene
New World TMT Ltd
New World TMT Ltd investment in Series C - Adagene
AVIC Trust
AVIC Trust investment in Series C - Adagene
Sequoia Capital China
Sequoia Capital China investment in Series C - Adagene
King Star Capital
King Star Capital investment in Series C - Adagene
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-12 | Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board |
Official Site Inspections
http://www.adagene.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.59 K
- Host name: ec2-52-36-16-193.us-west-2.compute.amazonaws.com
- IP address: 52.36.16.193
- Location: Boardman United States
- Latitude: 45.8491
- Longitude: -119.7143
- Metro Code: 810
- Timezone: America/Los_Angeles
- Postal: 97818
More informations about "Adagene"
Company Overview - Adagene
Our discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be first or best in class. We have forged strategic partnerships with multiple …See details»
Adagene - Crunchbase Company Profile & Funding
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which …See details»
About - Adagene
Toggle navigation. 简体中文. English; 简体中文See details»
Adagene, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor …See details»
Adagene Inc. (ADAG) Company Profile & Facts - Yahoo Finance
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates …See details»
Adagene - LinkedIn
At Adagene, every day is a step towards advancing cancer treatment. Our dynamic antibody development platform and precision masking technology bring new hope to patients worldwide.See details»
Adagene Appoints Cuong Do to Board of Directors and Audit …
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of …See details»
Adagene Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Adagene has 5 employees across 3 locations and $18.11 m in annual revenue in FY 2023. See insights on Adagene including office locations, competitors, revenue, financials, …See details»
Adagene Announces Appointment of Interim Chief Medical Officer …
Aug 12, 2021 SAN FRANCISCO, Calif. and SUZHOU, China, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform …See details»
Adagene Announces Board and Management Appointments to …
SAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of …See details»
Collaborations - Adagene
We are establishing a global network of partnerships and collaborations – from discovery to development. These alliances leverage our AI-powered antibody technology platform to help …See details»
Adagene Presents Preclinical Data Showcasing Best-in-Class …
Dec 13, 2021 All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward …See details»
Adagene Reports Full Year 2020 Financial Results and Provides …
Mar 31, 2021 SAN FRANCISCO and SUZHOU, China, March 31, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage …See details»
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and ...
Mar 7, 2024 Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (TREGs) in the tumor …See details»
Adagene Achieves $3 Million Milestone in Collaboration with …
May 4, 2023 SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology …See details»
Adagene Reports Full Year 2023 Financial Results and Provides
Mar 29, 2024 --Adagene Inc., a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today …See details»
Adagene Announces First Patients Dosed in Global Phase 1 Clinical …
Mar 16, 2021 SAN FRANCISCO, Calif. and SUZHOU, China, March 16, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company …See details»
Adagene Presents Data Demonstrating First and Best-in-Class …
Apr 8, 2022 All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward …See details»
Publications - Adagene
ADG126. Deciphering Improved Clinical Therapeutic Index (TI) of Muzastotug (ADG126), a Masked Anti-CTLA-4 SAFEbody ® over its Unmasked Form (ADG116) as Monotherapy or in …See details»